Partnership of Sonrai and AOA Dx aims to accelerate creation of diagnostic test for ovarian cancer
Partnership Announcement: Sonrai Analytics and AOA Dx Collaborate to Develop Revolutionary Ovarian Cancer Test
Sonrai Analytics and AOA Dx have announced a strategic partnership aimed at developing a groundbreaking multi-omic liquid biopsy test for ovarian cancer. This collaboration brings together two innovative entities, with Sonrai Analytics offering its bioinformatics expertise and AOA Dx focusing on the creation of the first diagnostic test for ovarian cancer in symptomatic women [1].
The partnership will focus on integrating multi-omic data — combining genomics, proteomics, and transcriptomics — in a liquid biopsy format. This minimally invasive test, using blood samples, could lead to earlier and more accurate diagnoses of ovarian cancer in patients experiencing symptoms.
The test is based on a unique combination of novel gangliosides, lipids, and proteins. Sonrai Analytics will provide its cloud-based advanced analytics platform, pharma-grade data infrastructure, and bioinformatic expertise to support AOA in validating diagnostic biomarkers. This collaboration will unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers and enabling earlier and more accurate detection [1].
AOA's Chief Scientific Officer, Dr Abigail McElhinny, stated that the partnership will allow AOA to integrate and manage their in-house development data, cross-reference it with public datasets, and analyze it seamlessly within one centralized environment.
Meanwhile, in the field of digital health and AI news, PathAI has received FDA clearance for its AISight Dx platform. This development underscores the growing importance of AI and digital health technologies in the diagnostic sector.
Separately, b-rayZ has become Affidea's AI Partner for breast imaging. However, this partnership is not related to ovarian cancer diagnostics.
AbbVie, another player in the healthcare industry, has received marketing authorisation from MHRA, as reported in the Femtech News section.
As the partnership between Sonrai Analytics and AOA Dx progresses, further details about the test’s specific technology, timeline, and clinical validation are expected to be revealed. This collaboration promises to be a significant step forward in the early detection and treatment of ovarian cancer.
[1] Source: [Link to the original source if available]
- The collaboration between Sonrai Analytics and AOA Dx, focusing on ovarian cancer, will leverage artificial intelligence, as Sonrai Analytics provides its cloud-based advanced analytics platform.
- In a related development, the field of digital health and AI is growing, as evident from PathAI receiving FDA clearance for its AISight Dx platform.
- The test being developed by Sonrai Analytics and AOA Dx, for ovarian cancer diagnosis, will integrate multi-omic data science to provide a minimally invasive, multi-modal test using blood samples.
- The early detection and treatment of ovarian cancer may see significant advancements with the progress of the Sonrai Analytics and AOA Dx partnership, as they work towards developing a revolutionary multi-omic liquid biopsy test.
